- Title: Subtitle
- ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
- Creators
- M. Poon - National University HospitalJ. Walewski - Państwowy Instytut BadawczyT. M. Kim - Seoul National University HospitalS. Cho - The Catholic University of Korea Seoul St. Mary's HospitalI. Jarque - Hospital Universitari i Politècnic La FeE. Iskierka-Jażdżewska - University of ŁódźH. M. Prince - The University of MelbourneS. Y. Oh - Dong-A University HospitalF. Lim - Singapore General HospitalC. Carpio - Universitat Autònoma de BarcelonaT. Tan - Koo Foundation Sun Yat-Sen Cancer CenterS. Ayyappan - University of IowaA. Gutierrez - Hospital Universitario Son EspasesJ. Li - Regeneron (United States)M. Ufkin - Regeneron (United States)M. Zhu - Regeneron (United States)A. Chaudhry - Regeneron (United States)H. Mohamed - Regeneron (United States)S. Ambati - Regeneron (United States)W. S. Kim - Samsung Medical Center
- Resource Type
- Abstract
- Publication Details
- Hematological oncology, Vol.41(S2), pp.141-142
- DOI
- 10.1002/hon.3163_93
- ISSN
- 0278-0232
- eISSN
- 1099-1069
- Language
- English
- Date published
- 06/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984442224102771
Abstract
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
Hematological oncology, Vol.41(S2), pp.141-142
06/2023
DOI: 10.1002/hon.3163_93
Details
Metrics
8 Record Views